← Back
Data updated: Mar 29, 2026
INNOGENIX
CardiovascularNeurologyOncology
Generics
INNOGENIX is a generic drug manufacturer focused on Cardiovascular, Neurology, Oncology.
1986
Since
5
Drugs
-
Trials
106
Approved (2yr)
Key Drugs
No active drugs
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Cardiovascular 50%
2 drugs
Neurology 25%
1 drugs
Oncology 25%
1 drugs
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Discontinued (2)
Company Info
- First Approval
- 1986-07-16
- Latest
- 2026-01-07
- Applications
- 5